Form D · Biotechnology

Pulse Therapeutics, Inc.

St. Louis, MO · CIK 0001518707

Offering snapshot reported Jan 27, 2016 · SEC filing

Reported sold
$5.62M
Offering amount: $13.8M
Investors reported
29
Form D · investor count
Minimum accepted
$10K
Reported outside-investor minimum
First sale
Jan 12, 2016
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 27, 2016Initial$5,615,708No comparison29SEC filing
Feb 6, 2014Initial$1,025,000No comparison3SEC filing
Dec 30, 2011Initial$3,090,000No comparison4SEC filing
Aug 1, 2011Amendment$1,650,000$325,000vs Apr 21, 20118SEC filing
Apr 21, 2011Initial$1,325,000No comparison5SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-256012

Source: Form D, filed Jan 27, 2016. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Amy L. Boyet Executive
Daniel J. Broderick Director
Francis M. Creighton Director, Executive
Peter S. Finley Executive
Eric A. Gulve Director
Thomas Hillman Director
Bevil J. Hogg Director
Eric Moessinger Director
Sean Morris Director, Executive
Rogers Ritter Executive
Peggy Stohr Executive
James C. Wachtman Executive
Stephen A. Wexler Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
911 Washington Avenue Suite 730
St. Louis, MO, 63101